ArticleTherapeutic advances in medical oncology2026
Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline low-level viremia in HBV-related hepatocellular carcinoma: prognostic significance, risk stratification, and clinical implications.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-level hepatitis B viremia is recognized as a potential driver of hepatocarcinogenesis; however, its prognostic impact on patients with advanced hepatocellular carcinoma (HCC) receiving systemic therapy remains poorly defined. Objective: To determine the independent prognostic impact of low-level viremia (LLV; HBV DNA 20-2000 IU/mL) compared with maintained virologic response (MVR; HBV DNA < 20 IU/mL) in patients with intermediate-to-advanced HBV-related HCC undergoing systemic therapy, and to evaluate whether on-treatment viral status serves as a superior predictor to baseline HBV DNA levels. Design: This was a multicenter retrospective cohort study. Methods: A total of 1814 patients treated at three centers between 2020 and 2024 were retrospectively enrolled. After ⩾4 months of follow-up, patients were classified into LLV ( Results: Multifactorial analysis identified HBeAg positivity (OR 1.971, 95% CI 1.53-2.541, Conclusion: LLV is a robust, independent indicator of poor prognosis in systemic-treated intermediate-to-advanced HBV-HCC and should be preferred to baseline HBV DNA load for risk stratification and to guide intensified antitumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.